Side-effects in women treated with adjuvant endocrine therapy for breast cancer

L. M. Rademaker; R. Gal; A. M. May; M. C.T. Batenburg; F. van der Leij; R. M. Bijlsma; H. M. Verkooijen; A. Doeksen; M. F. Ernst; D. J. Evers; C. C. van der Pol; E. M. Monninkhof

doi:10.1016/j.breast.2025.104416

Side-effects in women treated with adjuvant endocrine therapy for breast cancer

L. M. Rademaker, R. Gal, A. M. May, M. C.T. Batenburg, F. van der Leij, R. M. Bijlsma, H. M. Verkooijen, A. Doeksen, M. F. Ernst, D. J. Evers, C. C. van der Pol, E. M. Monninkhof^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

1 Downloads (Pure)

Abstract

Many women with breast cancer prematurely discontinue adjuvant endocrine therapy, leading to increased mortality. We performed a cross-sectional survey (n = 456) within the Dutch UMBRELLA-cohort to gain insight into the prevalence of side-effects and its association with premature discontinuation. Almost all current endocrine therapy users experienced side-effects (92.7 %), most frequent were vasomotor- and musculoskeletal symptoms. The most reported reason for premature discontinuation was side-effects (88.1 %). Former treatment with chemotherapy was associated with more reported side-effects (97.2 % vs 82.5 %, ORadj 6.31), but less premature discontinuation of endocrine therapy (18.6 % vs 28.6 %, p-value 0.016).

Original language	English
Article number	104416
Journal	Breast
Volume	80
Early online date	11 Feb 2025
DOIs	https://doi.org/10.1016/j.breast.2025.104416
Publication status	Published - Apr 2025

Keywords

Adjuvant therapy
Discontinuation of therapy
Endocrine therapy
ER positive
Side-effects

Access to Document

10.1016/j.breast.2025.104416Licence: CC BY

PIIS0960977625000359Final published version, 503 KBLicence: CC BY

Cite this

@article{b4db68bc065348a4b74fc06985bcad16,

title = "Side-effects in women treated with adjuvant endocrine therapy for breast cancer",

abstract = "Many women with breast cancer prematurely discontinue adjuvant endocrine therapy, leading to increased mortality. We performed a cross-sectional survey (n = 456) within the Dutch UMBRELLA-cohort to gain insight into the prevalence of side-effects and its association with premature discontinuation. Almost all current endocrine therapy users experienced side-effects (92.7 %), most frequent were vasomotor- and musculoskeletal symptoms. The most reported reason for premature discontinuation was side-effects (88.1 %). Former treatment with chemotherapy was associated with more reported side-effects (97.2 % vs 82.5 %, ORadj 6.31), but less premature discontinuation of endocrine therapy (18.6 % vs 28.6 %, p-value 0.016).",

keywords = "Adjuvant therapy, Discontinuation of therapy, Endocrine therapy, ER positive, Side-effects",

author = "Rademaker, {L. M.} and R. Gal and May, {A. M.} and Batenburg, {M. C.T.} and {van der Leij}, F. and Bijlsma, {R. M.} and Verkooijen, {H. M.} and A. Doeksen and Ernst, {M. F.} and Evers, {D. J.} and {van der Pol}, {C. C.} and Monninkhof, {E. M.}",

note = "Publisher Copyright: {\textcopyright} 2025 The Authors",

year = "2025",

month = apr,

doi = "10.1016/j.breast.2025.104416",

language = "English",

volume = "80",

journal = "Breast",

issn = "0960-9776",

publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Side-effects in women treated with adjuvant endocrine therapy for breast cancer

AU - Rademaker, L. M.

AU - Gal, R.

AU - May, A. M.

AU - Batenburg, M. C.T.

AU - van der Leij, F.

AU - Bijlsma, R. M.

AU - Verkooijen, H. M.

AU - Doeksen, A.

AU - Ernst, M. F.

AU - Evers, D. J.

AU - van der Pol, C. C.

AU - Monninkhof, E. M.

PY - 2025/4

Y1 - 2025/4

N2 - Many women with breast cancer prematurely discontinue adjuvant endocrine therapy, leading to increased mortality. We performed a cross-sectional survey (n = 456) within the Dutch UMBRELLA-cohort to gain insight into the prevalence of side-effects and its association with premature discontinuation. Almost all current endocrine therapy users experienced side-effects (92.7 %), most frequent were vasomotor- and musculoskeletal symptoms. The most reported reason for premature discontinuation was side-effects (88.1 %). Former treatment with chemotherapy was associated with more reported side-effects (97.2 % vs 82.5 %, ORadj 6.31), but less premature discontinuation of endocrine therapy (18.6 % vs 28.6 %, p-value 0.016).

AB - Many women with breast cancer prematurely discontinue adjuvant endocrine therapy, leading to increased mortality. We performed a cross-sectional survey (n = 456) within the Dutch UMBRELLA-cohort to gain insight into the prevalence of side-effects and its association with premature discontinuation. Almost all current endocrine therapy users experienced side-effects (92.7 %), most frequent were vasomotor- and musculoskeletal symptoms. The most reported reason for premature discontinuation was side-effects (88.1 %). Former treatment with chemotherapy was associated with more reported side-effects (97.2 % vs 82.5 %, ORadj 6.31), but less premature discontinuation of endocrine therapy (18.6 % vs 28.6 %, p-value 0.016).

KW - Adjuvant therapy

KW - Discontinuation of therapy

KW - Endocrine therapy

KW - ER positive

KW - Side-effects

UR - http://www.scopus.com/inward/record.url?scp=85217955309&partnerID=8YFLogxK

U2 - 10.1016/j.breast.2025.104416

DO - 10.1016/j.breast.2025.104416

M3 - Article

C2 - 39978152

AN - SCOPUS:85217955309

SN - 0960-9776

VL - 80

JO - Breast

JF - Breast

M1 - 104416

ER -

Side-effects in women treated with adjuvant endocrine therapy for breast cancer

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this